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Abstract
Background: Lung cancer is the most common cause of cancer related death worldwide and survival is poor.
Patients with lung cancer may develop a critical illness, but it is unclear what features are associated with an
Intensive Care Unit (ICU) admission.
Methods: This retrospective, observational, population-based study of linked cancer registration, ICU, hospital
discharge and mortality data described the factors associated with ICU admission in patients with lung cancer. The
cohort comprised all incident cases of adult lung cancer diagnosed between 1st January 2000 and 31st December
2009 in the West of Scotland, UK, who were subsequently admitted to an ICU within 2 years of cancer diagnosis.
Multiple logistic regression was used to determine factors associated with admission.
Results: 26,731 incident cases of lung cancer were diagnosed with 398 (1.5%) patients admitted to an ICU. Patients
were most commonly admitted with respiratory conditions and there was a high rate of invasive mechanical
ventilation. ICU, in-hospital and six-month survival were 58.5, 42.0 and 31.2%, respectively. Surgical treatment of
lung cancer increased the odds of ICU admission (OR 7.23 (5.14–10.2)). Odds of admission to ICU were reduced
with older age (75-80 years OR 0.69 (0.49–0.94), > 80 years OR 0.21 (0.12–0.37)), female gender (OR 0.73 (0.59–0.90))
and radiotherapy (OR 0.54 (0.39–0.73)) or chemotherapy treatment (OR 0.52 (0.38–0.70)).
Conclusion: 1.5% of patients diagnosed with lung cancer are admitted to an ICU but both short term and long
term survival was poor. Factors associated with ICU admission included age < 75 years, male gender and surgical
treatment of cancer
Background
Lung cancer is the most common cancer and the leading
cause of cancer related death worldwide [1]. Due to the
nature of the disease and the aggressive treatments often
employed, patients with lung cancer may develop a crit-
ical illness such that they require admission to ICU for
invasive monitoring or treatment [2]. Of all the individ-
ual cancer types, lung cancer has one of the poorest sur-
vival after an ICU admission and has been demonstrated
to have a high ICU and in-hospital mortality [3–5]. A
systematic review of published outcomes for patients
with solid tumours admitted to ICU described an aver-
age ICU mortality of 40.1% for patients with lung cancer,
the highest of all the individual tumour types described
[3]. However, lung cancer is one of the commonest
tumour types admitted to ICU [2, 6, 7].
The proportion of cancer patients that are admitted to
ICU is steadily increasing with one US hospital describ-
ing a two-fold increase in the number of lung cancer pa-
tients admitted to ICU over a ten-year period [8]. A
wide variety of factors have been reported to be inde-
pendently associated with short term mortality, the
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majority being related to the severity of the acute epi-
sode of illness requiring critical care and degree of organ
dysfunction. However, no previously published studies
have attempted to describe which factors are associated
with ICU admission for these patients.
The aim of this study was to describe the rate of crit-
ical illness resulting in ICU admission among patients
with lung cancer and the factors associated with this.
We performed a population-based study using linked
cancer registry, hospitalisation, ICU audit and death re-
cords to determine the risks after a cancer diagnosis.
Methods
Study design, Population & Setting
We conducted a retrospective, observational, multi-centre,
population-based study through an analysis of secondary
data comprising linked cancer registration, hospital dis-
charge, intensive care and mortality records. Full details
are described elsewhere [2]. Patients resident in the West
of Scotland who had a diagnosis of lung cancer (ICD-10
codes; C33, C34.0, C34.1, C34.2, C34.3, C34.8 and C34.9)
on the Scottish Cancer Registry between 1st January 2000
and 31st December 2009 were included in this study.
Small Cell Lung Cancers (SCLC) were classified as ICD-O
morphology M 8041/3 to M 8045/9; all others were classi-
fied Non-Small Cell Lung Cancers (NSCLC). We investi-
gated whether they had been admitted to one of the 16
general ICUs located in the region within 2 years of the
date of cancer incidence up to 31/12/2011. The first ad-
mission to an ICU within 2 years following a diagnosis of
lung cancer was identified and linked to the appropriate
individual episode of hospital care. We used death and
hospital discharge records to identify whether patients
died during their hospital stay.
Data sources and variables
The study used four linked data sets: the Scottish Cancer
Registry, Scottish Morbidity Record 01, national death re-
cords and the Scottish Intensive Society Audit Group
WardWatcher ICU database. WardWatcher collects data
on patient demongraphics, admitting specialty, admission
diagnosis, the Acute Physiology and Chronic Health
Evaluation (APACHE) II scoring system, and the type of
organ support. Organ support was defined as receipt of in-
vasive mechanical ventilation, vasoactive drugs to provide
cardiovascular support, or renal replacement therapy.
Socioeconomic status was measured using the Scottish
Index for Multiple Deprivation (SIMD 2009 V2 Scotland)
quintile, an aggregate measure used to identify small area
concentrations of deprivation.
The SMR01 hospital discharge records were reviewed
for all primary and secondary diagnoses in the 5 years
preceding the date of lung cancer incidence. These ICD-
9 or ICD-10 coded diagnoses were computed to
determine the presence or absence of co-morbid disease
according to the Charleson Comorbidity Index (CCI)
through previously published coding algorithms [9, 10].
This study was approved by the West of Scotland Re-
search and Ethics Committee. Approvals to use the data
were obtained from the West of Scotland Critical Care
Research Network, SICSAG, and the West of Scotland
Cancer Surveillance Unit.
Statistical analyses
Patients who were admitted to an ICU were compared
to the remainder of the incident lung cancer cohort ac-
cording to demographic, clinical and cancer-related vari-
ables. Summary statistics including mean and standard
deviation or median and inter-quartile range were deter-
mined for continuous exposure variables accordingly.
Categorical variables were summarised according to fre-
quencies and proportions. Non-ordered categorical vari-
ables were analysed by a chi-squared test of association
whilst ordinal variables were compared between the two
groups by use of a chi-squared test for trend.
Factors associated with admission to ICU were esti-
mated using a multivariable logistic regression model.
The odds of survival were computed for each exposure
variable using univariable analyses with 95% confidence
intervals and P values. Variables found to have a poten-
tially statistically significant alteration in the odds of sur-
vival (P < 0.3) in univariable analyses were included in an
adjusted multivariable model. The cancer treatment mo-
dalities (surgery, radiotherapy, chemotherapy) were not
included in any multivariable model due to potential col-
linearity with treatment intent. A P value of < 0.05 was
used to identify statistically significant associations in
multivariable modelling for ICU admission.
Statistical analyses were performed using StataCorp
2011 (Stata Statistical Software: Release 12).
Availability of data and materials
The authors do not have permission to share the data
used for this article, however, the data can be accessed
via application to the Information Services Division of
NHS Scotland.
Results
There were 26,731 incident cases of primary lung cancer
diagnosed during the study period of whom 398 patients
(1.5%) were admitted to an ICU within 2 years of diagno-
sis. Figure 1 shows the cumulative hazard curve for time
to admission to ICU in days according to sex. There ap-
pears to be a sharp rise in the hazard of ICU admission
within the first 100 days following a diagnosis of lung can-
cer for both sexes. The median number of days from lung
cancer diagnosis to admission was 52 (IQR 0–106). There
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were fewer ICU admissions amongst women observed
than were expected.
Features pertaining to the ICU admission are detailed in
Table 1. The majority of lung cancer patients admitted to
ICU were following surgical hospitalisations. Common
causes for admission to ICU included lower respiratory
tract infection (27.4%), conditions directly related to lung
cancer such as bronchial obstruction or bronchial haem-
orrhage (20.3%), and following lung resection surgery
(15.3%). Organ support was frequently utilised with 40.1%
of patients requiring multi-organ support. ICU and hos-
pital median length of stay were 3 (IQR 1–6) and 10 days
(IQR 1–19). The proportions of patients who survived
ICU, hospital and six-months after hospital discharge were
58.5, 42.0 and 31.2%, respectively.
Table 2 compares the 398 patients admitted to ICU
within 2 years of diagnosis to the remaining 26,333 incident
primary lung cancer cases. Patients admitted to ICU had a
younger age of diagnosis than the non-ICU cohort. There
was a larger proportion of males admitted to ICU (61.8%)
than the remainder of the cohort (53.5%). The largest
SIMD quintile represented in each group was the most de-
prived but deprivation was not associated with admission
to ICU. Non-Small Cell Lung cancer was the commonest
tumour type in both the ICU and non-ICU groups with a
higher proportion in the ICU group (92% versus 84%). Co-
morbidity was common in both groups (39.9% ICU admis-
sions vs. 35.8% of non-ICU admissions, p 0.09). Those
admitted to an ICU were more likely to have undergone a
surgical treatment for lung cancer with a curative treatment
plan. Treatment with radiotherapy or chemotherapy oc-
curred in a higher proportion of the non-ICU population.
Table 3 describes factors associated with ICU admission
on univariable and multivariable logistic regression ana-
lysis. The largest effect was seen for patients receiving sur-
gical treatment for cancer, with OR 7.23 (95% CI 5.14–
10.2) for ICU admission, when compared to patients that
did not receive surgical intervention. Unknown treatment
intent was associated with ICU admission to a lesser ex-
tent (OR 1.54 (95% CI 1.08–2.20)). Increasing age, female
gender and radiotherapy or chemotherapy treatment were
all associated with a reduced odds of ICU admission in
the multivariable model.
Discussion
In a large inclusive cohort of lung cancer patients diag-
nosed over a ten-year period, we found that 1.5% were
admitted to a general ICU within 2 years of diagnosis.
ICU admission was greatest in the period shortly after
cancer diagnosis and this is likely to reflect patients de-
veloping critical illness as a consequence of active cancer
or its treatment.
Clinical features in patients with lung cancer admitted to
ICU
Reasons for ICU admission were predominantly related to
respiratory conditions with lower respiratory tract infec-
tions and complications from the malignancy accounting
for 27.4 and 20.3% of all admissions respectively. However,
the ICU admission was entirely unrelated to the lung can-
cer diagnosis/ treatment in one in four ICU lung cancer
patients. The majority of ICU patients with lung cancer
required organ support, the most common modality being
Fig. 1 Cumulative hazard of admission to Intensive Care by time since cancer incidence date according to sex (log-rank test for equality of
survivor functions Chi2 15.22, P < 0.001)
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invasive ventilation (70.9%) reflecting the high incidence
of respiratory disorders.
For patients admitted to ICU, mortality in ICU, hospital
and six-months post admission were 41.5, 58.0 and 68.8%,
respectively. Mortality in our study was relatively high
when compared with previous multi-centre studies [11–
13]. The largest study of this nature was performed on the
American surveillance, epidemiology and end results-
medicare registry (SEER), including nearly 50,000 patients.
Hospital mortality was reported as 24%, significantly lower
than that seen in this study. However, mortality at six-
months was similar at 65% [13]. This registry-based study
did not detail any of the features of the critical illness
which has been demonstrated to be the largest determin-
ant of short-term mortality [3]. Soares et al conducted the
only prospective, multi-centre cohort study and reported
ICU, in-hospital and six-month mortality of 28, 39 and
55% respectively. However, the proportion of subjects re-
quiring mechanical ventilation was only 53% compared
with the 79% observed in our study, suggesting that the
burden of critical illness was less.(11).
Differences between ICU and non-ICU groups
While the majority of patients with lung cancer were
treated with palliative intent, a disproportionate number of
patients in the ICU group had received curative treatment
with the majority of patients receiving surgical interven-
tion. This observation likely reflects clinician behaviour
whereby patients with curative treatment intent are prefer-
entially selected for ICU during an acute critical illness.
However, this could also be partially attributable to post-
operative complications in patients undergoing curative
surgical procedures as the majority of ICU admissions
were surgical in nature (66%) and ICU admission was dir-
ectly related to cancer surgery in 15%.
Factors associated with ICU admission in patients with
lung cancer
Surgical treatment of cancer was found to be the stron-
gest predictor of ICU admission with a seven-fold in-
crease in odds of ICU admission compared with those
not treated with surgery. This may be due to critical ill-
ness occurring at the time of surgery with one in eight
ICU admissions were directly attributable to the surgical
Table 1 Clinical features of Lung cancer patients admitted to
ICU
Categories N = 368
N (%)
Admission Diagnosis
Related to lung cancer 81 (20.3)
Acute cardiac decompensation 43 (10.8)
Chest infection 109 (27.4)
Related to surgical treatment 61 (15.3)
Unrelated to lung cancer 104 (26.1)
Cardiac Arrest Precipitating Admission
Prior CPR 29 (7.3)
No prior CPR 369 (92.7)
APACHE II Score
8–12 20 (5.0)
13–17 67 (16.8)
18–22 77 (19.4)
23–27 74 (18.6)
≥ 28 55 (13.8)
Missing 105 (26.4)
Admission Specialty
Medical 134 (33.7)
Surgical 264 (66.3)
Number of Organs Supported
None 79 (19.9)
1 94 (23.6)
2 138 (34.7)
3 25 (6.3)
Not known 62 (15.6)
Receipt of Mechanical Ventilation
No 99 (24.9)
Yes 282 (70.9)
Not known 17 (4.3)
Receipt of Renal Replacement Therapy
No 322 (80.9)
Yes 27 (6.8)
Not known 49 (12.3)
Receipt of Vasoactive Agents
No 183 (46.0)
Yes 182 (45.7)
Not known 33 (8.3)
Charlson Co-Morbidity Index
0 239 (60.1)
≥ 1 159 (39.9)
Length of stay
ICU 3 days (IQR 1–6)
Hospital 10 days (IQR 1–19)
Table 1 Clinical features of Lung cancer patients admitted to
ICU (Continued)
Categories N = 368
N (%)
Mortality
ICU 165 (41.5)
Hospital 231 (58.0)
Six-month 274 (68.8)
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treatment. While it is possible that patients having re-
ceived curative surgery were being considered better
candidates for ICU, treatment intent was not associated
with ICU admission on the multivariable model. Other
treatment interventions influenced ICU admission by
reducing the odds by approximately half in those who
were treated with chemotherapy or radiotherapy com-
pared with those who were not. As these patients are be-
ing admitted early after diagnosis they may not have had
the opportunity to receive these treatment interventions
prior to ICU admission.
Age of incidence was found to be a strong negative pre-
dictor of ICU admission with a reduction in the odds of ad-
mission with increasing age above 75 years that reduces
further for those aged over 80 years. Previous work by
Azoulay et al. demonstrated that the largest influence on a
refusal for ICU admission in critically ill patients with can-
cer was an age of over 65 years [14]. Within the general
ICU population, increasing age has been associated with
poorer survival both in the short and longer term, and that
this was particularly pronounced for patients aged over 75
years [15]. It seems unlikely that critical illness is less com-
mon with increasing age, particularly given the increased
incidence of comorbidities encountered in an elderly popu-
lation, rather that concerns about poor outcomes in the
elderly patients swings the balance of benefit versus harm
away from ICU admission.
Comorbidity was not associated with an increase in odds
of ICU admission in the multivariable model. The study by
Slatore et al. [16] demonstrated that comorbidity has been
associated with poorer outcome after ICU admission in pa-
tients with lung cancer, however, our study suggests that
this does not necessarily influence admission patterns.
Females had a statistically significant reduction in the
odds of ICU admission compared to males (OR 0.75,
95% CI 0.61–0.92, P = 0.006). An increased incidence of
critical illness in men has been described for patients
with severe sepsis and trauma [17, 18]. The cause of this
is not clear but may reflect differences in lifestyle
choices, health behaviours or the impact of hormones
on stress responses. Furthermore, it is possible that the
gender difference may not reflect difference in rates of
critical illness but a difference in preferences for end of
life care. It is known from other studies that survival
from lung cancer is poorer in men than women overall.
Table 2 Features of lung cancer patients that are and are not
admitted to Intensive Care
ICU Admissions
N = 398
n (%)
Non-admissions
N = 26,333
n (%)
P value
Age at Incidence
Mean (SD) 67 (SD 8.8) 71 (SD 10.3) < 0.001
Sex
Male 246 (61.8) 14,085 (53.5) 0.001
Female 152 (38.2) 12,248 (46.5)
SIMD Quintile
1 (Most deprived) 146 (36.7) 10,691 (40.6) 0.350a
2 106 (26.6) 6692 (25.4)
3 73 (18.3) 4108 (15.6)
4 43 (10.8) 2739 (10.4)
5 (Most affluent) 30 (7.5) 2103 (8.0)
Histology
SCLC 32 (8.0) 4222 (16.0) < 0.001
NSCLC 366 (92.0) 22,111 (84.0)
Charlson Co-Morbidity Index
0 239 (60.1) 16,894 (64.2) 0.090
≥ 1 159 (39.9) 9439 (35.8)
Year of Cancer Incidence
2000 43 (10.8) 2562 (9.7) 0.004a
2001 39 (9.8) 2389 (9.1)
2002 42 (10.6) 2624 (10.0)
2003 57 (14.3) 2600 (9.9)
2004 35 (8.8) 2607 (9.9)
2005 42 (10.6) 2609 (9.9)
2006 38 (9.5) 2738 (10.4)
2007 46 (11.6) 2716 (10.3)
2008 35 (8.8) 2700 (10.3)
2009 21 (5.3) 2788 (10.6)
Treated with Surgery
No 168 (42.2) 21,540 (81.8) < 0.001
Yes 210 (52.8) 2505 (9.5)
Not known 20 (5.0) 2288 (8.7)
Treated with Radiotherapy
No 280 (70.4) 15,510 (58.9) < 0.001
Yes 53 (13.3) 7876 (29.9)
Not known 65 (16.3) 2947 (11.2)
Treated with Chemotherapy
No 283 (71.1) 17,342 (65.9) < 0.001
Yes 56 (14.1) 6468 (24.6)
Not known 59 (14.8) 2523 (9.6)
Therapy objectives
Curative 140 (35.2) 2481 (9.4) < 0.001
Table 2 Features of lung cancer patients that are and are not
admitted to Intensive Care (Continued)
ICU Admissions
N = 398
n (%)
Non-admissions
N = 26,333
n (%)
P value
Palliative 184 (46.2) 20,657 (78.5)
Not known 74 (18.6) 3195 (12.1)
SCLC Small cell lung cancer, NSCLC Non-small cell lung cancer
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Among those with a critical illness that we report, sur-
vival was also poorer in men than women. Given that a
minority of lung cancer patients is admitted to an ICU
(1.5%), we would conclude that both non-critically ill as
well as critically ill female lung cancer patients have bet-
ter survival than men.
Strengths and weaknesses
Our study has a number of strengths. It is the first study
to compare lung cancer patients admitted to an ICU
with those who were not over a ten-year period. It uti-
lised a large sample size and was conducted across mul-
tiple general rather than oncological ICUs, which may
improve its generalisability. We used datasets with high
levels of case ascertainment for cancer incidence, hospi-
talisation and deaths. Measurement bias was reduced
through the use of objective scoring systems to capture
acute illness and past medical history. The use of the
SIMD provided a robust, multi-dimensional measure of
socioeconomic status rather than relying on a single
Table 3 Factors associated with ICU admission on univariable and multivariable logistic regression
Univariable
Odds Ratio (95% CI)
P value Multivariable
Odds Ratio (95% CI)
P value
Age at Incidence Quintile*
15–62 1 1
63–69 1.21 (0.93–1.57) 0.153 1.15 (0.88–1.51) 0.294
70–74 0.90 (0.67–1.20) 0.463 0.87 (0.64–1.17) 0.360
75–80 0.62 (0.46–0.85) 0.003 0.69 (0.49–0.94) 0.019
> 80 0.16 (0.09–0.28) < 0.001 0.21 (0.12–0.37) < 0.001
Sex
Male 1 1
Female 0.71 (0.58–0.87) 0.001 0.73 (0.59–0.90) 0.003
SIMD Quintile
1 (Most deprived) 1 1
2 1.16 (0.90–1.49) 0.249 1.16 (0.89–1.50) 0.269
3 1.30 (0.98–1.73) 0.068 1.37 (1.03–1.83) 0.033
4 1.15 (0.82–1.62) 0.425 1.31 (0.92–1.86) 0.132
5 (Most affluent) 1.04 (0.70–1.55) 0.829 1.08 (0.69–1.55) 0.696
Therapy Objectives
Curative 1 1
Palliative 0.16 (0.13–0.20) < 0.001 1.08 (0.75–1.54) 0.682
Not known 0.41 (0.31–0.55) < 0.001 1.54 (1.08–2.20) 0.017
Treated with Surgery
No 1 1
Yes 10.75 (8.7–13.2) < 0.001 7.23 (5.14–10.2) < 0.001
Not known 1.12 (0.70 - 1.79) 0.631 0.50 (0.27–0.91) 0.025
Treated with Radiotherapy
No 1 1
Yes 0.37 (0.28–0.50) < 0.001 0.54 (0.39–0.73) < 0.001
Not known 1.22 (0.93–1.60) 0.150 1.32 (0.78–2.24) 0.298
Treated with Chemotherapy
No 1 1
Yes 0.53 (0.40–0.71) < 0.001 0.52 (0.38–0.70) < 0.001
Not known 1.43 (1.08–1.90) 0.013 1.07 (0.62–1.84) 0.814
Charlson Co-morbidity Index
0 1 1
≥ 1 1.19 (0.97–1.46) 0.091 1.22 (0.99–1.51) 0.059
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domain as a proxy for affluence as in previous studies
[12, 13, 19]. Exposure variables from the ICU admission
were collected and determined prospectively thereby re-
ducing the likelihood of misclassification.
This study has several limitations. Large proportions of
missing data precluded the use of information on ethnicity,
cancer stage and pathological sub-division which could
confound the observed associations. Furthermore, while
the date of cancer diagnosis in all cases was prior to ICU
admission, we could not determine the certainty of diagno-
sis at the point of entry to critical care which may affect
decisions about whether to admit a patient. We accept that
approaches to managing critical illness are likely to differ
in patients receiving palliative care and while we adjusted
for treatment objective (curative, palliative or unknown),
we did not have information on palliative care involvement
within the data sources utilised in this study.
Conclusion
Lung cancer is the most common cause of cancer re-
lated death worldwide [1]. Our results highlight that
only a small proportion of patients with lung cancer
were subsequently admitted to an ICU within 2 years of
diagnosis (1.5%). Over half of those who were admitted
survived to ICU discharge with nearly a third surviving
to six-months from admission. It is unclear why some
factors that are usually associated with a better progno-
sis, such as younger age and surgical treatment, are asso-
ciated with greater risks of ICU admission. This may
represent physician decision making and further pro-
spective research is needed to explore the clinical path-
ways prior to ICU admission.
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